New combo therapy for CLL tested in Real-World settings
NCT ID NCT07602088
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is looking at how well a combination of two drugs, ibrutinib and venetoclax, works for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Researchers will follow 60 patients who are already scheduled to receive this treatment to see how many respond and what factors influence doctors' decisions. The goal is to understand the real-world effectiveness of this fixed-duration therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibrutinib and venetoclax
What this could lead to
If successful, this study could confirm that a fixed-duration combination of ibrutinib and venetoclax is effective and practical for routine treatment of CLL, potentially offering a time-limited therapy option.
What could go wrong
This is an observational study with only 60 participants, so results may not apply to all patients. The combination can cause side effects like heart rhythm problems, bleeding, or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Spitalul Universitar de Urgenta Bucuresti
RECRUITINGBucharest, 050098, Romania